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Neutrophil migration into injured tissues is invariably accompanied
by pain. Bv8/prokineticin 2 (PK2), a chemokine characterized by a
unique structural motif comprising five disulfide bonds, is highly
expressed in inflamed tissues associated to infiltrating cells. Here,
we demonstrate the fundamental role of granulocyte-derived PK2
(GrPK2) in initiating inflammatory pain and driving peripheral
sensitization. In animal models of complete Freund’s adjuvant-
induced paw inflammation the development and duration of pain
temporally correlated with the expression levels of PK2 in the
inflamed sites. Such an increase in PK2 mRNA depends mainly on
a marked up-regulation of PK2 gene transcription in granulocytes.
A substantially lower up-regulation was also detected in macro-
phages. From a pool of peritoneal granulocytes, elicited in rats by
oyster glycogen, we purified the GrPK2 protein, which displayed
high affinity for the prokineticin receptors (PKRs) and, when
injected into the rat paw, induced hypersensitivity to noxious
stimuli as the amphibian prokineticin Bv8 did. Mice lacking PKR1 or
PKR2 developed significantly less inflammation-induced hyperal-
gesia in comparison with WT mice, confirming the involvement of
both PKRs in inflammatory pain. The inflammation-induced up-
regulation of PK2was significantly less in pkr1 null mice than inWT
and pkr2 null mice, demonstrating a role of PKR1 in setting PK2
levels during inflammation. Pretreatment with a nonpeptide PKR
antagonist, which preferentially binds PKR1, dose-dependently
reduced and eventually abolished both prokineticin-induced hy-
pernociception and inflammatory hyperalgesia. Inhibiting PK2 for-
mation or antagonizing PKRs may represent another therapeutic
approach for controlling inflammatory pain.
hypernociception  inflammation  prokineticin receptors
In past years, several groups have generated convincing evi-dence that neutrophil-associated hyperalgesia results from the
neutrophil release of proinflammatory pronociceptive factors,
including products of arachidonic acid metabolism (1, 2) and
cytokines such as IL-1, IL-8, IL-12, TNF-, and macrophage
inflammatory proteins MIP-1a and MIP-1b (3, 4). Belonging to
the chemokine family, the recently discovered prokineticins
[Bv8,MIT, prokineticin 1 (PK1), and prokineticin 2 (PK2)] (5–9)
activate two G protein-linked PK receptors (PKR1 and PKR2)
(10–12) localized in the brain, dorsal root ganglia (DRG)
neurons, granulocytes, macrophages, and endothelial cells. Bv8
was initially identified in the skin secretion of the frog Bombina
variegata, as a secretory protein that induced hyperalgesia and
gastrointestinal motility. Later on, the human orthologues of this
highly conserved protein (PK1 or EG-VEGF and PK2 or
mammalian Bv8) were shown to promote angiogenesis and
modulate neurogenesis, circadian rhythms, hematopoiesis, and
immune response (13). Activation of PKRs in primary afferent
C fibers sensitizes nociceptors to thermal, mechanical, and
chemical stimuli (14–16). In neutrophils, macrophages, and
dendritic cells it promotes chemotaxis and cytokine release
(17–20), and in capillary endothelial cells it stimulates angio-
genesis (21). Testis, peripheral blood leukocytes, and macro-
phages express twomRNA transcripts of PK2, one coding for the
canonical PK2 and the other for an elongated form containing
additional 21 basic amino acids between Lys-47 and Val-48 of the
mature PK2 protein, named PK2L (6, 19, 22). In inflamed tissues
both PK2 and PK2L mRNA transcripts are overexpressed (15),
but the mature proteins have not yet been isolated from inflam-
matory cells nor tested for their biological activity.
The goal of the present experiments is to demonstrate that the
granulocyte-derived prokineticins may be major determinants in
triggering inflammatory pain and PKRs may represent a ther-
apeutic target for the development of novel peripherally acting
antinociceptive drugs. First, we demonstrate, in animal models
of inflammatory pain, that PK2 and PK2L expression levels
timely correlate with the beginning and development of pain
behavior. We identified the inflammatory cells that synthesize
PK2 proteins and investigated whether PK2 protein released by
these cells can produce hyperalgesia. Then, using pkr1- and
pkr2-null mice, we evaluated the role of PKRs in modulating PK2
expression levels and inflammatory hyperalgesia. Finally, we
studied the antinociceptive activity of a selective nonpeptide
PKR antagonist (23) in acute inflammatory pain.
Results
PK2 Expression Levels Timely Correlate with Development and Dura-
tion of Inflammatory Pain. Intraplantar (ipl) injection of complete
Freund’s adjuvant (CFA) produces an inflammatory reaction
with a concomitant swelling of the paw and hypernociception. In
both rats and mice the hyperalgesia was already evident 6 h after
injection, peaked at 24 h, and recovered to baseline levels in 72 h
in mice, but lasted longer in rats. Significant edema formation
occurred at the sixth hour. Swelling was maximal after 24 h,
then began to decrease. Paw volume returned toward normal
values in 3 days in mice, but in 1 week or more in rats. In both
rats and mice PK2 mRNA expression levels in the paw tissue
correlate with the time course of the CFA-induced hyperalgesia
(Fig. 1). RT-PCR analysis performed on rat pad skin (Fig. 2A),
collected at several time points after saline or CFA injection,
revealed that expression levels of PK2 and PK2L in saline-
injected paws were about equally low. In CFA-injected paws PK2
and PK2L expression strongly increased, reaching levels several
hundred-fold higher than in the contralateral saline-injected paw
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(900 105 copy number per ng RNA vs. 1 1 copy number per
ng RNA). PK2 expression wasmaximal from 9 to 24 h then began
to decrease. At 72 h, it was still 10 times higher than in the
control paw. PK2L peaked at 9 h and returned to normal levels
in 72 h. In mice (Fig. 2B), in saline- and CFA-injected paws the
expression levels of PK2L were significantly lower than those of
PK2 (0.02 0.01 and 1.3 1 copy number per ng RNA vs. 1.8
1 and 160  25 copy number per ng RNA). PK2 was strongly
up-regulated by CFA injection, reaching at 12 h an expression
level 120-fold higher than in contralateral saline-injected paw. In
both rats and mice PKR1 transcripts peaked 24 h after CFA
injection, reaching levels 15- to 30-fold higher than those in the
contralateral noninflamed paw (20 3 vs. 0.6 0.5 copy number
per ng RNA in rats; 12.5  3 vs. 0.65  0.5 copy number per ng
RNA in mice). PK1 and PKR2 transcript levels were very low
and did not change after CFA injection.
In situ hybridization with radiolabeled PK2 riboprobes was
performed on sections of mouse paw 12 h after CFA or saline
injection. Strong signal was evident only in CFA-injected paws,
mainly around vessels, which probably was associated with infil-
trating cells (Fig. 3).
PK2 and PKR1 mRNA in Cells Sorted from CFA-Injected Mouse Paw.To
identify the cells expressing PK2 and quantitate transcript levels
of PK2 and PKR1 we prepared cell suspensions from mouse
paws collected 12 and 24 h after CFA or saline injection. To
obtain enough material we pooled inflamed paws of 20 mice for
each point. Flow cytometric analysis indicated that neutrophils
(Mac-1Gr-1) were more abundant than macrophages (Mac-
1Gr-1) in the paws collected 12 h after CFA (18  3% and
9  3% of total isolated cells, respectively), but macrophages
became as abundant as neutrophils 24 h after CFA injection
(25  4% and 22  5%, respectively). CD3 lymphocytes were
undetectable. There were no detectable infiltrating cells in
noninflamed paw; hence we used neutrophils and macrophages
obtained from the spleen of control mice as a model of nonac-
tivated immune cells. RT-PCR analysis performed on neutro-
phils and macrophages sorted from spleen of control mice
demonstrated that neutrophils are the major source of PK2
mRNA (PK2 copy number per ng RNA: 23 in neutrophils vs. 3
in macrophages). The paw inflammation induced a marked PK2
up-regulation in both spleen (2,500 copy number per ng RNA)
and paw (2,060 copy number per ng RNA) neutrophils. A
substantially lower up-regulation (8- to 10-fold) was detected in
macrophages (Fig. 4A). PKR1 transcript levels were comparable
in neutrophils and macrophages from spleen of control mice.
The inflammation did not change PKR1 levels in neutrophils but
increased it 3 times in activated macrophages (Fig. 4B).
Granulocyte-Derived PK2 (GrPK2) Induces Hyperalgesia. In rats, i.p.
injection of oyster glycogen induced marked extravasation of
granulocytes into the peritoneal cavity and decreased the sys-
temic nociceptive threshold as assessed with the paw-pressure
test. Hyperalgesia started 2 h after i.p. injection was maximal
Fig. 1. Correlation between the time course of PK2 mRNA expression in
inflamed paws (right y axis) and hyperalgesia (left y axis) after ipl injection of
CFA in rats (A) and mice (B).
Fig. 2. Time course of PK2, PK2L, and PKR1 expression in rat and mouse paw
tissue after ipl CFA, evaluated by real-time RT-PCR. (A) In rats expression levels
of PK2 and PK2L were comparable. (B) In mice the expression levels of PK2L
were significantly lower than those of PK2. In both rats and mice PKR1
transcripts peaked 24 h after CFA injection. Results are presented as input copy
number of the gene of interest per ng of total RNA.
A B
Fig. 3. Autoradiographic images of inflamed mouse paw section (12 h after
CFA) hybridized with 35S-PK2 antisense riboprobe and counterstained with
toluidine blue–light green solution. (A) PK2 riboprobe revealed PK2 mRNA
(black granules) in PMNs along the capillary wall and into extravascular space
of the derma (40). (B) Higher magnification (100) of PK2-expressing gran-
ulocytes.








from 6 to 9 h, then decreased showing normal values 12 h after
i.p. injection (see Fig. 8F). Control rats, i.p.-injected with saline,
did not show any changes in the paw-pressure threshold over a
9-h observation period. RT-PCR analysis demonstrated that
extravasated peritoneal granulocytes, collected 6 h after glyco-
gen injection, express PK2 mRNA at levels enormously higher
(10,500  900 copy number per ng mRNA) than the peritoneal
granulocytes collected 6 h after saline injections (2.3  2 copy
number per ng mRNA) (Fig. 5A). Gel electrophoresis of RT–
PCR amplification products demonstrated that oyster glycogen-
elicited peritoneal granulocytes express both PK2 isoforms, the
canonical PK2 similar to the amphibian Bv8 and the long form,
PK2L, already described in mouse and human testis (6, 22).
Strong signal corresponding to PKR1mRNA is also evident (Fig.
5B). 2D electrophoresis of peritoneal granulocyte proteins re-
vealed a spot of10 kDa and 8.9 pI that subsequent purification
steps and biological tests allowed us to identify as authentic rat
PK2 (Fig. 5C). We did not identify any PK2L-like protein. The
PK2 protein purified from rat peritoneal granulocytes (GrPK2)
concentration-dependently displaced 125I-MIT from membrane
preparation of CHO cells stably transfected with the PKR1 (Fig.
5D) and, when injected ipl in rats, produced Bv8-like hyperal-
gesia that was antagonized by prior administration of the PKR1-
preferring antagonist PC1 (0.01 g/ipl) (Fig. 5E). Starting with
2  109 peritoneal granulocytes, the estimated yield in Bv8-like
protein was 320 ng. Analysis of the N-terminal fragment
(PRIMM) revealed the amino acid sequence AVITGACDKD
that perfectly matches that of rat PK2 (Swiss Protein Bank
accession no. NM138852).
Involvement of the PKRs in Inflammation-Induced Hyperalgesia and
PK2 Up-Regulation. In WT mice CFA-induced inflammation re-
duced paw withdrawal latency to the noxious thermal stimulus and
greatly up-regulated PK2 mRNA with respect to noninflamed paw
(saline). In comparison with WT-mice, pkr1 (15) or pkr2 gene
disruption significantly reducedCFA-induced inflammatory hyper-
sensitivity, but only the pkr1 gene disruption reduced inflammatory
PK2 mRNA up-regulation. Indeed, PK2 transcript levels 12 h after
CFA injection were 15-fold lower in pkr1-null mice than in WT
mice, whereas PK2 transcript levels in pkr2-null mice were similar
to those in WT mice. These results indicate that, although both
PKRs modulate inflammatory pain, PKR1 alone is involved in
modulating in pkr1-null mice PK2 expression (Fig. 6).
PKR Antagonism Is a Novel Pharmacological Strategy for the Therapy
of Inflammatory Pain. The nonpeptide PKR1-preferring antag-
onist PC1 (23), preinjected (0.01 g per paw) into paws of mice
(Fig. 7), antagonized the hyperalgesic effect of exogenous Bv8
(0.5 ng per paw) but was inefficacious against other proalgesic
mediators such as bradykinin (2 g per paw), prostaglandin E2
(PGE2) (1 g per paw), and 2-methylthioATP (100 nmol per
paw) (Fig. 7). PC1 local (0.01–0.05 g per paw) and systemic
(up to 150 g/kg) injection did not change basal thermal and
mechanical pain threshold in rats and mice. Moreover, in rats
and mice, PC1 antagonized CFA-induced inf lammatory pain.
In mice, ipl injection of 0.01 g of PC1 abolished the inf lam-
mation-induced thermal hypernociception (Fig. 8A) and 0.05
g of PC1 ipl. abolished the reduction in the body weight-
bearing of the inf lamed paw as assessed by the incapacitance
test (Fig. 8B) for 1 h. Indeed, CFA-induced inf lammation
caused a significant reduction in body weight distribution
(ratio  0.6) across the hind limbs, as the mice placed less
weight through the ipsilateral limb. PC1 (0.05 g, ipl) allowed
Fig. 4. PK2 (A) and PKR1 (B) expression in immune cells purified by FACS from
spleen of saline- or 12-h CFA-injected mice, and from paws of 12- and 24-h
CFA-injected mice. Inflammation dramatically increased PK2 expression in
neutrophils and slightly increased PKR1 expression in macrophages. PKR1
expression was 3-fold higher with respect to control cells. Results are pre-
sented as input copy number of the gene of interest per ng of total RNA.
Fig. 5. Purification of GrPK2. (A) PK2 mRNA expression levels in peritoneal
granulocytes collected 6 h after i.p. injection of saline (CO) or oyster glycogen
(TR). (B) Gel electrophoresis of PK2, PK2L, and PKR1 transcripts, amplified by
RT-PCR, in oyster glycogen-elicited peritoneal granulocytes. (C) 2D electro-
phoresis of peritoneal granulocyte proteins revealed a spot of10 kDa and 8.9
pI. (D) Displacement curve of 125I-MIT from membrane preparations of PKR1-
transfected CHO cells by graded concentrations of Bv8. Granulocyte extract
(step C fractions) corresponding to 3 107 and 3 108 cells displaced 125I-MIT
as 0.7 and 6 nM Bv8, respectively. (E) Time course of hyperalgesia induced
in rats by ipl injection of Bv8 (0.5 ng) or GrPK2 corresponding to 3  106 cell
lysate after pretreatment with saline or the PKR1-preferring antagonist PC1
(0.01 g/ipl).
Fig. 6. In WT mice CFA-induced paw inflammation reduced the paw with-
drawal latency (left y axis, paw immersion test, 48 °C) with respect to saline-
injected paw (4 vs. 12 s). Withdrawal latency of inflamed paw was significantly
longer in pkr1- and pkr2-null mice than in WT mice, whereas inflammation-
induced PK2 up-regulation (right y axis) was significantly lower in pkr1-null
mice than in WT and pkr2-null mice.
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the animals to distribute their body weight equally across both
hind limbs (ratio  1, as control mice).
In rats, paw injection of 0.01 g of PC1 abolished the inflam-
mation-induced mechanical hypernociception for 2 h. The noci-
ceptive threshold of the inflamed paw rapidly increased, reaching
values near those of the contralateral noninflamed paw in15 min
(Fig. 8C). The longer duration of effect of PC1 in mechanical
hyperalgesia in rats (Fig. 8C) compared with the effect in thermal
hyperalgesia in mice is probably caused by different pharmacoki-
netics in the two species. Indeed increasing the PC1 doses in mice
(0.05–0.2 g ipl) prolongs the antihyperalgesic effect up to 2–3 h
(Fig. 8A). Also by s.c. injection, PC1 (20, 50, and 150 g/kg) raised
the pressure pain threshold of the inflamed paw toward the
threshold value of the control paw. The antihyperalgesic effect was
dose-dependent and lasted for 2 h (Fig. 8D). Repeated systemic
administration of PC1 (150 g/kg at 6 and 24 h after CFA) also
reduced the paw edema and accelerated the recovery to normal
paw volume after the insult. The PK2 expression levels, assessed 2
days after CFA injection, were significantly lower (4-fold) in the
inflamed paws of PC1-treated rats than in the inflamed paws of
saline-treated rats (Fig. 8E). PC1 (150 g/kg, s.c.) abolished the
systemic mechanical hyperalgesia caused by oyster glycogen-
induced peritonitis (Fig. 8F).
Discussion
We have previously demonstrated that systemic or local injections
of very low doses (in the range of fmol) of the amphibian proki-
neticin Bv8 decrease nociceptive thresholds to thermal,mechanical,
and chemical stimuli by activating PKR1 and PKR2 in the primary
sensory neurons. This increase in nociceptor excitability resulted
from functional cooperation between PKR1 and TRPV1, the two
receptors being coexpressed in small sensory neurons of DRG
(14–16).
Leukocytes of myeloid origin are a major source of endogenous
mammalian Bv8, i.e., the PK2. Bv8/PK2 is overexpressed in in-
flamed tissue associated to infiltrating cells, hence Bv8/PK2 could
be a link between polimorphonuclear cells (PMN) infiltrating the
inflamed tissue and the development of inflammatory pain. Here,
we demonstrate that the development and duration of CFA-
induced hyperalgesia correlates with the expression level of PK2 in
the inflamed paw, granulocytes infiltrating the tissue are the
inflammatory cells overexpressing PK2, and the PK2 protein,
isolated from peritoneal granulocytes, produces Bv8-like hyperal-
gesia by selectively binding the PKRs. We also demonstrate that
blocking the PKRs by a nonpeptide selective PKR antagonist
abolishes hypernociception in inflammatory models as well as the
deletion of either PKR gene does.
The inf lammation produced by paw injection of CFA was of
higher intensity and longer duration in rats than in mice,
mirroring the increase in PK2 expression that was 10 times
higher in rats than in mice and lasted 12 h longer in rats.
Granulocytes are the major source of PK2 in the inf lamed paw
skin; moreover the granulocytes sorted from the mouse paw
12 h after CFA injection are richer in PK2 mRNA than those
sorted after 24 h (Fig. 4A), demonstrating a time dependency
in CFA-induced up-regulation of PK2 in granulocytes. Nev-
ertheless, granulocytes sorted from the spleen of inf lamed
mice showed elevated PK2 expression levels like those ob-
Fig. 7. Ipl injection of PC1 (0.05 g) did not change the basal thermal
nociceptive threshold of mice (paw-immersion test, 48 °C). Pretreatment with
PC1 (0.01 g, ipl) abolished the thermal hyperalgesia induced by Bv8 (0.5 ng,
ipl), but was ineffective in antagonizing the hyperalgesia induced by ipl
administration of BK (2 g) and PGE2 (1 g) (left y axis) and in reducing the
paw-lifting time caused by ipl injection of ATP (100 nmol) (right y axis).
Fig. 8. Antihyperalgesic and antinflammatory effect of ipl and s.c. injection of the PKR1-preferring antagonist PC1 in mice and rats. (AandB) In mice ipl injection
of PC1 24 h after CFA reverted the thermal hyperalgesia (0.01, 0.05, and 0.2g) for 1–3 h (A) and abolished the CFA-induced reduction in the body weight-bearing
of the inflamed paw (0.05g) for1 h (B). (C) In rats, PC1 (0.01g, ipl) reverted CFA-induced mechanical hyperalgesia for2 h. (D) In rats, PC1 dose-dependently
antagonized the CFA-induced hyperalgesia also by systemic injections (20–150 g/kg, s.c.), bringing the nociceptive threshold of inflamed paw toward that of
contralateral noninflamed paw. (E) In rats, repeated administration of PC1 (150 g/kg, s.c.), at 6 and 24 h after CFA injection, accelerated recovery of inflamed
paw to normal paw volume and significantly reduced the inflammation-induced PK2 up-regulation (Inset). In rats, i.p. injection of oyster glycogen induced
marked extravasation of granulocytes into peritoneal cavity and decreased the nociceptive threshold evaluated with the paw-pressure test. PC1 (150 g/kg, s.c.)
abolished the systemic hyperalgesia caused by GrPK2, released into circulation. (F) Intraperitoneal injection of saline did not modify the mechanical nociceptive
threshold (CO).








served in granulocytes sorted from inf lamed paws and were
100 times higher than PK2 levels in granulocytes sorted from
the spleen of noninf lamed mice. These results indicate that the
inf lammatory response induced by local CFA injection am-
plifies PK2 gene transcription in PMN not only locally in the
paw but also systemically. The mechanism of inf lammation-
induced PK2 gene transcription in granulocytes is yet un-
known. Inf lammatory stimuli in mice and rats are known to
produce an early and rapid increase in plasma levels of
granulocyte colony-stimulating factor (G-CSF) (24), and,
among the numerous cytokines released by inf lammatory
stimulation, G-CSF is the only cytokine able to activate PK2
transcription in CD11bGr1 bone marrow-derived cells
(25). G-CSF is a principal regulator of granulopoiesis and
neutrophil mobilization from the bone marrow; thus, the early
increase of G-CSF levels in plasma of CFA-inf lamed animals
could explain the enhanced PK2 transcription in spleen and
paw granulocytes.
To support the hypothesis that granulocyte-released Bv8-like
proteins directly modulate inflammatory pain, we isolated from
granulocyte extracts a single protein that in vitro bound PKR1
and in vivo induced a Bv8-like hyperalgesia. This protein dis-
played molecular mass, isoelectric point, and N-terminal amino
acid sequence identical to those reported for rat PK2. However,
rat inflammatory granulocytes also express high levels of PK2L
mRNA, a splice variant of Bv8/PK2 gene, encoding a 21-aa insert
rich (19 of 21) in basic residues. The biological role of PK2L is
still unknown. In functional assays and receptor binding assays
the recombinant PK2L protein demonstrated very poor activity,
whereas the hypothesized smaller peptide PK2L, derived by
proteolytic cleavage of PK2L, retains selective affinity for PKR1
(26, 27). However, these putative proteins were apparently
absent in our extracts. These data may be interpreted as gran-
ulocytes being unable to translate PK2L transcript into proteins
or release such a highly basic protein (pI11) or our nociceptive
and receptor-binding assays may not be sensitive enough to
detect the very low biological activities of PK2L and PK2 (26,
27). Whatever the underlying reason, the 10 times higher PK2
expression level in rat inflamed paw than in mice inflamed paw
might explain the stronger inflammatory response in rats than
in mice.
Because prokineticins are potent chemoattractans formonocytes
andmacrophages both in vitro and in vivo and are able to stimulate
the release of proinflammatory and proalgesic cytokines from
macrophages (17–20) and monocytes (28) we can further hypoth-
esize that PK2, released at the site of inflammation, represents a
component of the cytokine–chemokine loop in inflammatory pain,
which is initiated by the arrival of granulocyte and maintained by
the subsequent recruitment of monocytes and macrophages. In-
flammatory stimuli activate the release of the cytokine G-CSF that
stimulates the synthesis and release of the chemokine PK2 by
neutrophils, and this chemokine, in turn, stimulates macrophage
chemotaxis and cytokine release by recruited macrophages. Al-
though other leukocyte-derived chemokines are known to produce
hypernociception in rats and mice (2, 29, 30) their pronociceptive
activity and potency in activating G protein-coupled receptors is
100–500 times lower than that of PK2, and their receptors are far
less abundant than PKRs in the primary sensory neurons under
basal conditions (15, 16, 31, 32).
Producing CFA inflammation in mice lacking the pkr1 or pkr2
gene demonstrated that both PKR1 and PKR2 modulate pain
perception, but only PKR1 modulates PK2 expression. Indeed,
neither pkr1- nor pkr2-null mice developed inflammatory ther-
mal hypernociception, confirming our hypothesis that CFA-
induced hyperalgesia highly depends on the activation of PKRs
of nociceptive terminals by granulocyte-released PK2. Con-
versely, pkr1- but not pkr2-null mice displayed significantly less
inflammation-induced PK2 up-regulation than WT mice, dem-
onstrating an involvement of PKR1 in setting the enhanced PK2
expression level in inflammation.We have already demonstrated
the functional role of macrophage PKR1, which is responsible
for chemotaxis and proinflammatory activity (19). Ferrara’s
group (17, 25) demonstrated that PK2 directly promotes survival
and differentiation of granulocytic and monocytic lineages and,
in vivo, increases the number of circulating leukocytes and
synergizes with G-CSF in mobilization of CD11bGr1 cells to
the peripheral blood. Hence, GrPK2 released at the site of
inflammation may activate the functional receptor, PKR1,
present on granulocytes and macrophages, promoting their
recruitment and survival by paracrine or autocrine mechanisms.
If Bv8/PK2 is a fundamental chemokine for the development
of inflammatory pain, blocking the PKRs could potentially have
two beneficial effects: an analgesic or, better, antihyperalgesic
effect and a reduction of the inflammatory process as we
demonstrated here by treating the animals with the nonpeptide
PKR1-preferring antagonist PC1 (23). PC1, by local or systemic
injection in both rats and mice, increased the nociceptive thresh-
old of the inflamed paw toward the values of the control paw,
leaving the pain threshold of control noninflamed paw un-
changed. Furthermore, the mechanical hyperalgesia in the in-
flamed paw was so strongly reduced by PC1 that mice were
enabled to bear body weight on the inflamed paw.
The rapid onset of PC1-induced antihyperalgesic effect sug-
gests a direct antagonism at the PKRs of primary nociceptors.
Indeed, PC1 antagonized the Bv8-induced hyperalgesia but not
the hypernociception produced by proalgesic molecules such as
PGE2, bradykinin, and ATP. Antihyperalgesic doses of PC1 also
reduced paw edema in rats and accelerated the recovery of
normal paw volume after the inflammatory insult. Two days
after CFA injection, the paw volume of PC1-treated rats was
approximately half that of saline-treated rats, and the PK2
expression level in the paw of PC1-treated rats was five times
lower than in the paw of saline-treated rats, indicating that
blocking PKR1 impairs granulocytes to up-regulate PK2, as pkr1
knockout did. Thus, our results indicate that a faster reduction
of PK2 at the site of inflammation allows for faster healing.
Moreover, s.c. injection of PC1 antagonized the systemic hyper-
algesia produced by glycogen-induced peritonitis in rats, indi-
cating that this inflammatory hypernociception may be linked to
the release of PK2 from peritoneal granulocytes into circulation.
These results suggest a fundamental role of the Bv8/
prokineticin system in inf lammatory pain, at least in rodents.
If this role can be confirmed in humans, the inhibition of
Bv8/PK2 formation or antagonism at PKRs, as shown here, will
constitute a promising strategy for a therapeutic approach to
controlling inf lammatory pain.
Materials and Methods
PK and PKR Gene Expression. Total RNA was prepared from mouse or rat tissue
samples by using a RNeasy Kit (Qiagen). cDNAs were amplified by real-time
PCR (iCycler; Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad). Rat primers
were: PK2, 5-CAAGGACTCTCAGTGTGGA-3 and 5-AAAATGGAACTTTC-
CGAGTC-3; PK2L, 5-AGGAAAGAAGAAGGGCGAAG-3 and 5-TCCTTAAA-
CATGCCAAACCTG-3. Rat PKR1 and PKR2 primers (16), mouse primers (15),
and cycling conditions (15, 16) have been reported. For sorted cells, real-time
RT-PCR was performed with the Quantitect SYBR one-step RT-PCR kit (Qiagen)
as described (20). cDNA standards for each analyzed gene were generated,
and serial dilutions ranging from 10 to 109 input copies were used as a
standard curve in each PCR run. The expression level of the gene of interest
was reported as input copy number per ng of total RNA.
In Situ Hybridization. cDNA fragments for mouse PK2 (GenBank accession no.
AF487280, nucleotides 24–504) were obtained by RT-PCR and subcloned into
the pGEM-T easy vector (Promega). [35S]UTP and [35S]CTP double-labeled
riboprobes were generated and tissues were processed as described (15).
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Flow Cytometry and Cell Sorting. Freshly isolated cells from mouse spleen were
prepared and stained as described (33). Paw tissue samples were harvested 12
and 24 h after injection of CFA to obtain a single cell suspension as reported
(34). Cells were counted and analyzed on a FACSCalibur with CellQuest
software (BD Biosciences). PE-anti-Gr-1 (RB6–8C5) and FITC-anti-Mac-1 (M1/
70) antibodies were purchased from BD Biosciences. For cell sorting, cells were
appropriately stained, and Mac-1Gr-1 and Mac-1Gr-1 populations
were purified (purity 95%) with a FACSAria sorter (BD Biosciences).
Purification and Isolation of Prokineticins from Peritoneal Granulocytes. Peri-
tonitis was induced in male Sprague–Dawley rats (n  100) by i.p. adminis-
tration of oyster glycogen (1% in PBS), and the extravasated cells were
collected 6 h later (35). The purity of granulocytes, as assessed by Wright-
stained smears, was 95%. Harvested cells were washed, centrifuged at
4,000  g at 4 °C, resuspended, and lysed with 2D Protein Extraction Buffer I
(GE). After centrifugation, an aliquot of the supernatant (1/20 volume) was
submitted to 2D electrophoresis to separate granulocyte proteins, and the
remaining supernatant was added to 4 volumes of 0.2% TFA in acetonitril/
isopropanol (4:1). The extract was centrifuged at 4,000 g for 10 min at 4 °C,
and the supernatant was collected and stored at 80 °C (step A).
First-dimension isoelectric focusing was performed by means of Bio-Rad
Protean IEF Cell using 17-cm Bio-Rad ReadyStrip IPG strips, pH 3–10. Second-
dimension SDS/PAGE was performed by means of Bio-Rad PROTEAN II XL cell
using the Protean II Ready Gel precast gels in Tris/glycine/SDS running buffer,
pH 8.5. In SDS/PAGE electrophoretic gels protein spots were revealed with the
silver-staining method.
The extract (step A) was lyophilized, dissolved in 20 mM sodium phosphate
buffer (pH 6.4), loaded on cationic exchanger Source 30S column (GE), and eluted
by a gradient 0–100% of 0.4 M NaCl in 20 mM sodium phosphate buffer, pH 6.4
(step B). Eluates containing hyperalgesic activity (from 25 to 35% of 0.4 M NaCl)
were reunited and further purified by gel filtration [Superdex 75 10/300 column
(GE), eluting buffer 1 M acetic acid, 1 mL/min, UV detection 220 and 280 nm] to
eliminate salts that interfere with binding assay (step C). Collected fractions were
assayed, in vivo, for the presence of Bv8-like hyperalgesic activity and, in vitro, for
PKR1 binding assay on PKR1-transfected CHO cells. The fractions containing
bioactivity were reunited, lyophilized, dissolved in 0.2% TFA in water, loaded on
a reversed-phase C8 column (Vydac), and eluted by a gradient 15–100% aceto-
nitril containing 0.2% TFA (step D). The biological active fraction (PKR1 binding)
was further chromatographed on a Grace-Vydac 238 EV 51 column before sub-
mitting to sequence analysis (PRIMM).
Receptor Binding Assay. The fractions purified by gel filtration (step C) were
evaluated for their ability to displace [125I]MIT binding from membrane prep-
arations of PKR1-transfected CHO cells as described (36). The displacement
curve of 125I-MIT by graded concentrations of Bv8 (0.01–100 nM) was used to
generate a standard curve to determine the content of Bv8-like proteins in
each tested fraction (PRISM; GraphPad).
Animals and Hypernociceptive Tests. All experiments were performed under
protocols approved by the Animal Care and Use Committee of the Italian
Ministry of Health according to European Commission directives. Male Spra-
gue–Dawley rats (250–300 g), C57BL/6 (25–30 g), pkr1(/) and pkr1(/),
and pkr2(/) and pkr2(/) mice (Lexicon Genetics) were housed in tem-
perature-controlled rooms (22–25 °C) with access to water and food ad libi-
tum. Pain threshold was evaluated by the paw-pressure test in rats and the
paw-immersion-in-hot-water test (48 °C) in mice as described (14, 15). Mice
were tested for changes in mechanical hypersensitivity by using a body weight
bearing averager (Incapacitance Tester; Biological Instruments). Results were
expressed as mean ipsilateral/contralateral ratio. The data are presented as
mean  SE mean values.
Inflammatory PainModels.Peritonitis was induced in rats by i.p. administration
of oyster glycogen as described above. Paw inflammation was induced by ipl
injection of CFA (Sigma) in mice (20L per paw) and rats (100L per paw). Paw
volume was measured with a 7140 plethysmometer (Ugo Basile).
Drug Injections. Drugs were injected topically into the plantar region of
hindpaws (ipl), in volumes of 20 L in mice and 100 L in rats and s.c. into the
flank region in a volume of 2 mL/kg. GrPK2 (isolated from peritoneal granu-
locytes) and amphibian Bv8 (purified from skin secretion of B. variegata) (5)
were injected ipl in mice and rats. PC1 synthesized by Balboni et al. (23) was
injected ipl and s.c. in mice and rats. Bradykinin (Sigma–Aldrich), PGE2 (Sigma–
Aldrich), and 2-methylthioATP (Tocris) were injected ipl in mice.
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